These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29759689)

  • 41. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual-coil vs single-coil active pectoral implantable defibrillator lead systems: defibrillation energy requirements and probability of defibrillation success at multiples of the defibrillation energy requirements.
    Schulte B; Sperzel J; Carlsson J; Schwarz T; Ehrlich W; Pitschner HF; Neuzner J
    Europace; 2001 Jul; 3(3):177-80. PubMed ID: 11467457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.
    DeWitt ES; Triedman JK; Cecchin F; Mah DY; Abrams DJ; Walsh EP; Gauvreau K; Alexander ME
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1057-63. PubMed ID: 25262116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of an active abdominal pulse generator on defibrillation thresholds with a dual-coil, transvenous ICD lead system.
    Rashba EJ; Farasat M; Kirk MM; Shorofsky SR; Peters RW; Gold MR
    J Cardiovasc Electrophysiol; 2006 Jun; 17(6):617-20. PubMed ID: 16836709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.
    Bettin M; Larbig R; Rath B; Fischer A; Frommeyer G; Reinke F; Köbe J; Eckardt L
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1499-1506. PubMed ID: 29759830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Temporal Trends in and Factors Associated With Use of Single- Versus Dual-Coil Implantable Cardioverter-Defibrillator Leads: Data From the NCDR ICD Registry.
    Pokorney SD; Parzynski CS; Daubert JP; Hegland DD; Varosy PD; Curtis JP; Al-Khatib SM
    JACC Clin Electrophysiol; 2017 Jun; 3(6):612-619. PubMed ID: 29759435
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal method to achieve consistently low defibrillation energy requirements.
    Winter J; Zimmermann N; Lidolt H; Dees H; Perings C; Vester EG; Poll L; Schipke JD; Contzen K; Gams E
    Am J Cardiol; 2000 Nov; 86(9A):71K-75K. PubMed ID: 11084103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Shock efficacy of single and dual coil electrodes-new insights from the NORDIC ICD Trial.
    Bänsch D; Bonnemeier H; Brandt J; Bode F; Svendsen JH; Ritter O; Aring J; Gutleben KJ; Schneider R; Felk A; Hauser T; Buchholz A; Hindricks G; Wegscheider K
    Europace; 2018 Jun; 20(6):971-978. PubMed ID: 28419217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.
    Brouwer TF; Yilmaz D; Lindeboom R; Buiten MS; Olde Nordkamp LR; Schalij MJ; Wilde AA; van Erven L; Knops RE
    J Am Coll Cardiol; 2016 Nov; 68(19):2047-2055. PubMed ID: 27810043
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validation of the PRAETORIAN score in a large subcutaneous implantable cardioverter-defibrillator collective: Usefulness in clinical routine.
    Doldi F; Frommeyer G; Löher A; Ellermann C; Wolfes J; Güner F; Zerbst M; Engelke H; Korthals D; Reinke F; Eckardt L; Willy K
    Heart Rhythm; 2024 Jul; 21(7):1057-1063. PubMed ID: 38382685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients.
    Pokorney SD; Hellkamp AS; Yancy CW; Curtis LH; Hammill SC; Peterson ED; Masoudi FA; Bhatt DL; Al-Khalidi HR; Heidenreich PA; Anstrom KJ; Fonarow GC; Al-Khatib SM
    Circ Arrhythm Electrophysiol; 2015 Feb; 8(1):145-51. PubMed ID: 25504649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Two-incision versus three-incision implantation technique of subcutaneous implantable cardioverter defibrillator: Systematic review and meta-analysis of 2076 patients.
    Elkasaby MH; Khalefa BB; Yassin MNA; El-Hameed MMA; Elkoumi O; Al Hennawi H
    Pacing Clin Electrophysiol; 2024 Feb; 47(2):281-291. PubMed ID: 38071455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
    Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of the subcutaneous implantable cardioverter-defibrillator for reducing sudden cardiac death.
    Sanghera R; Sanders R; Husby M; Bentsen JG
    Ann N Y Acad Sci; 2014 Nov; 1329():1-17. PubMed ID: 25308791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of high defibrillation threshold.
    Uyguanco ER; Berger A; Budzikowski AS; Gunsburg M; Kassotis J
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1237-48. PubMed ID: 18939911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients.
    Zhang Y; Blasco-Colmenares E; Harms AC; London B; Halder I; Singh M; Dudley SC; Gutmann R; Guallar E; Hankemeier T; Tomaselli GF; Cheng A
    Europace; 2016 Sep; 18(9):1383-90. PubMed ID: 26498162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies.
    Makki N; Swaminathan PD; Hanmer J; Olshansky B
    Europace; 2014 Jan; 16(1):55-62. PubMed ID: 24058182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Outcomes of Single- versus Dual-Chamber Implantable Cardioverter Defibrillators: Lessons from the Israeli ICD Registry.
    Konstantino Y; Haim M; Boxer J; Goldenberg I; Feldman A; Michowitz Y; Glikson M; Suleiman M;
    J Cardiovasc Electrophysiol; 2016 Jun; 27(6):718-23. PubMed ID: 26852908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.